2,740 search results for “cancer drug discovery initiative” in the Public website
-
European Lead Factory
The European Lead Factory has been created with the ultimate goal to develop lead drug candidates to address neglected diseases including bacterial infections, psychiatric disorders and oncology.
-
Biological and Soft Matter Physics
Research groups in the Biological & Soft Matter Programme unravel mechanisms in biological processes and develop novel bio-inspired soft materials.
-
Ensnaring tumours in their own web
Erik Danen is looking at how to inhibit tumours that do not respond well to medicine – and he is making some headway. The Professor of Cancer Drug Target Discovery studies the interaction between tumour cells and their surroundings. Inaugural lecture on Friday 10 May.
-
Single cell technologies for mechanobiology and mechanopharmacology
Mechanobiology is a major area in biology, however, mechanics is currently a missing element in drug development pipelines. This has led to a high cost for the society. Mechanotoxicity of drugs often appears as a long-term side effect of drugs, and has led to removal of drugs from the market. Furthermore,…
-
Inhibitor Selectivity: Profiling and Prediction
Less than 1 in 10 drug candidates that enter phase 1 clinical trials actually gets approved for human use.
-
Predicting drug behaviour in the brain
Does a drug enter into the human brain once administered in the body?
-
The molecular secrets of medicinal cannabis
Chronic pain, nausea or vomiting due to chemotherapy. If you suffer from such ailments, medicinal cannabis can be a godsend. Though a downside is that it can make patients high. Therefore, Leiden researchers from the Oncode Institute are investigating alternatives that do not make you high. In Nature…
-
The body's own marijuana as inspiration for drug research
Endocannabinoids - the body's own marijuana - are promising departure points for drug research. Professor of Molecular Physiology Mario van der Stelt examines whether inhibiting their production can be a way to fight inflammatory brain disease and to combat obesity. Inaugural lecture 19 October.
-
Experimental drug BIA 10-2474 deactivates proteins in human nerve cells
At high doses, drug candidate BIA 10-2474 binds not only to the protein that it targets, but to other proteins as well. It thus deactivates proteins that are involved in the metabolism of nerve cells. This is what an international group of researchers from Leiden University and Erasmus MC, among others,…
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
NMR studies of protein-small molecule and protein-peptide interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal
-
ZF-HEALTH - Zebrafish Regulomics for Human Health
How can zebrafish research help understanding human diseases?
-
Predictive pharmacology
The aim of this research area is to be able to predict human drug response on the basis of mathematical models that are developed using preclinical experiments and prior knowledge.
-
Can we live longer? Leiden physicist makes discovery in protective layer in genes
With the aid of physics and a minuscule magnet, researchers have discovered a new structure of telomeric DNA. Telomeres are sometimes seen as the key to living longer. They protect genes from damage but get a bit shorter each time a cell divides. If they become too short, the cell dies. The new discovery…
-
Exhibition celebrates a century of astronomical discoveries
Some of the most significant and surprising astronomical breakthroughs that have shaped science, technology and culture over the last century are showcased in the Above and Beyond open-source exhibition. This exhibition was commissioned within the framework of the International Astronomical Union's…
-
CAM-PaC
The overall aim of CAM-PaC is to contribute to solving the socioeconomic and health challenges of PDAC by an integrative and systematic functional analysis of pancreatic cancer candidate genes. CAM-PaC will develop novel cellular and animal models, as well as novel strategies to analyse and integrate…
-
Organisation
The Leiden Academic Centre for Drug Research (LACDR) is responsible for the research and education in Bio-Pharmaceutical Sciences carried out at Leiden University.
-
Zware metalen hebben slechte reputatie, maar genezen ook kanker
Veel mensen denken dat zware metalen giftig zijn en mens en natuur altijd schade aanbrengen. Dat beeld moet genuanceerd worden, vindt hoogleraar Sylvestre Bonnet.
-
References to the Steel Industry in a Definitive GGD Report on Lung Cancer in the Dutch IJmond Region
Arco Timmermans is Professor by special appointment Public Affairs at the Institute of Public Administration. On Dutch television programme 'EenVandaag', he discussed the remarkable changes that have been made in a report on lung cancer in and around the Dutch city of Beverwijk that was presented by…
-
How Leiden's drug pioneers have switched to Covid research
From studying molecules in the blood of corona patients to developing a new concept for vaccines. The Leiden Academic Centre for Drug Research (LACDR) has transformed many ongoing projects into Covid research projects. Hubertus Irth, scientific director of LACDR, talks about the role of his institute…
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.
-
About the programme
The two-years MSc programme spans the entire spectrum of Analytical BioSciences, Biopharmaceutics, Drug Delivery Technology, Medicinal Chemistry, Pharmacology and Toxicology.
-
Targeting the adenosinergic system
Adenosine is an endogenous ligand which exerts its action by activating adenosine receptors (ARs), while its circulating levels are controlled via a variety of mechanism and proteins, amongst others the equilibrative nucleoside transporters (ENTs).
-
Microvasculature in Microfluidics: matching complexity with compatibility
In vitro disease models play a fundamental role in drug research. They enable the systemic identification and validation of disease mechanisms and the discovery of possible drug targets. However, more than often, drug candidates that are identified in vitro fail in the later clinical stages of drug…
-
From scientific idea to promising new drug
Many pharmaceutical companies no longer have their own lab and are working more closely with universities and start-ups of scientists. Professor of Science-Based Business Simcha Jong is researching how scientific ideas result in new drugs, including at the Leiden Bio Science Park (LBSP).
-
Programme structure
The Drug Discovery and Safety specialisation consists of compulsory and optional components.
-
Ton van Gestel
Faculty Governance and Global Affairs
a.f.j.c.van.gestel@fgga.leidenuniv.nl | +31 70 800 9589
-
Astonishing explorations at the Night of Discoveries
It was the Night of Discoveries on Saturday 16 September: a summer encounter between art and science. Leiden researchers from various disciplines inspired the public with their quest to understand our world.
-
From Descriptive to Predictive Pharmacology in Children using Semi-Physiological population modelling
An integrated approach of physiological concepts, advanced statistical approaches and large clinical datasets.
-
Animal Sciences
We perform multidisciplinary research at molecular, cellular, and organismal levels of animal biology to increase fundamental understanding of health and disease.
-
Resistance to PARP inhibition by DNA damage response alterations in BRCA1/2-deficient tumors
Inactivating mutations in BRCA1 or BRCA2 genes predispose to several types of cancer.
-
How to develop cancer drugs with less side effects
Lecture, Tuesday Talks: Science Insights
-
NMR Facility
Nuclear Magnetic Resonance (NMR) Spectroscopy is a non-destructive analytical technique that is used to study the nature and characteristics of molecules with an atomic level precision. It has a wide range of applications especially in synthetic chemistry, biological and biochemical research groups…
-
Knowledge of DNA repair in the fight against tumour cells
What is the most effective way to eliminate tumour cells? The DNA repair mechanism could play an important role in increasing the effectiveness of chemotherapy in the fight against cancerous cells. If we are to influence this mechanism, we need fundamental knowledge about how the mechanism works.
-
Using AI to improve the Design-Make-Test cycle with Galapagos
Researchers at LED3 are working together with biopharmaceutical company Galapagos to develop software for use in early drug discovery (funded by NWO). This software is able to design molecules with several simultaneously optimized characteristics and will also take prediction reliability into consideration…
-
History
Life Sciences Artificial Intelligence Data Science
-
Parameter optimization toward optimal microneedle-based dermal vaccination
Microneedle-based vaccination has several advantages over vaccination by using conventional hypodermic needles.
-
Professor Ewa Snaar-Jagalska appointed professor in the field of cellular tumor biology
From the 11th of May Ewa Snaar-Jagalska has been appointed Professor in the field of cellular tumor biology within the Faculty of Science at the Institute of Biology Leiden. Her research focuses on the cellular tumor biology and human cancer modeling in zebrafish
-
Societal impact
Research from the Living Lab is important for society. For example, scientists from the Living Lab discovered that the pesticide thiacloprid is up to 2,500 times more harmful to insects than was thought on the basis of regular lab research. Partly because of this discovery, the European Commission decided…
-
The scientists behind LED3
LED3 is the combined effort of three excellent institutes of Leiden University. Through joined hands, we are able to give rise to a more effective early drug discovery pipeline. Let us briefly introduce the three institutes.
-
Finding and valorizing new antibiotics using AI
Antibiotics are a class of medicine most people take for granted. But pathogenic bacteria are becoming more and more resistant to our antibiotics, and this poses a great challenge for future treatments. There is thus a great societal need to identify new molecules that can address new targets and be…
-
Light-activatable ruthenium-based anticancer prodrugs
Can light-activatable ruthenium compounds be used as a more selective anticancer treatment?
- About this minor
-
LACDR research project to develop novel engineering approaches to study cancer immunity
As part of the HTSM2017 funding program, the LACDR division for Systems Biomedicine and Pharmacology received 1.08 million euros for a research project to develop novel engineering approaches to fight cancer.
-
Quantitative Systems Pharmacology
This research area is focused on the development and application of novel concepts and models in the emerging area of quantitative systems pharmacology (QSP).
-
More effective blocking of CCR2 receptor
The discovery of new medicines is a tedious and lengthy process. On average, over 10,000 molecules need to be studied for one to become a drug and reach the patient. Part of that process are the very costly clinical trials in humans, and candidate drugs often fail due to side effects or lack of efficacy.…
-
Cryotomographic visualization of symbiosis initiation in the Euprymna scolopes-Vibrio fischeri association
The overall aim of this project is to understand, on the molecular level, how the bacterium V. fischeri cells interacts with their squid host.
-
Contact
Contact us about initial teacher education, educational research and teacher professional development
-
Strategy
The research area of this division is focused on the development of novel therapeutic modalities and novel concepts in early drug discovery, in order to better predict ligand-target interactions.
-
PKPD and disease modelling in therapy development for amyotrophic lateral sclerosis (ALS)
We aim to gain a better understanding of the natural disease progression of ALS in order to improve clinical trial design and analysis and to support drug discovery and clinical development of new drugs.